JP2019535746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535746A5 JP2019535746A5 JP2019527358A JP2019527358A JP2019535746A5 JP 2019535746 A5 JP2019535746 A5 JP 2019535746A5 JP 2019527358 A JP2019527358 A JP 2019527358A JP 2019527358 A JP2019527358 A JP 2019527358A JP 2019535746 A5 JP2019535746 A5 JP 2019535746A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- cancer
- haloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(*)[C@](C(N(CCC1)[C@]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=*)=O)N*(C)=C Chemical compound CC(C)(*)[C@](C(N(CCC1)[C@]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=*)=O)N*(C)=C 0.000 description 2
- NFLUBBOGFHPRKD-UHFFFAOYSA-N CCC(C)(C=C)NCC Chemical compound CCC(C)(C=C)NCC NFLUBBOGFHPRKD-UHFFFAOYSA-N 0.000 description 1
- GGZXJZZUBNDABX-SSDOTTSWSA-N CCCN(CC1)C[C@@H]1O Chemical compound CCCN(CC1)C[C@@H]1O GGZXJZZUBNDABX-SSDOTTSWSA-N 0.000 description 1
- VLLRBPIIWLQFCD-UHFFFAOYSA-N Cc1c(-c2ccc(CNC)cc2)[s]cn1 Chemical compound Cc1c(-c2ccc(CNC)cc2)[s]cn1 VLLRBPIIWLQFCD-UHFFFAOYSA-N 0.000 description 1
- ONYGKYUQGHVRKU-RXMQYKEDSA-N NNCC(N(CC1)C[C@@H]1O)=O Chemical compound NNCC(N(CC1)C[C@@H]1O)=O ONYGKYUQGHVRKU-RXMQYKEDSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425211P | 2016-11-22 | 2016-11-22 | |
| US62/425,211 | 2016-11-22 | ||
| PCT/US2017/063027 WO2018098288A1 (en) | 2016-11-22 | 2017-11-22 | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535746A JP2019535746A (ja) | 2019-12-12 |
| JP2019535746A5 true JP2019535746A5 (enExample) | 2020-12-24 |
Family
ID=62195636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527358A Pending JP2019535746A (ja) | 2016-11-22 | 2017-11-22 | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10925967B2 (enExample) |
| EP (1) | EP3544959A4 (enExample) |
| JP (1) | JP2019535746A (enExample) |
| KR (1) | KR20190080956A (enExample) |
| AU (1) | AU2017363265B2 (enExample) |
| CA (1) | CA3042294A1 (enExample) |
| WO (1) | WO2018098288A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| EP3544959A4 (en) * | 2016-11-22 | 2020-11-11 | Dana-Farber Cancer Institute, Inc. | BRUTON TYROSINE KINASE (BTK) DEGRADATION BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| CN109422752B (zh) * | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
| WO2019148150A1 (en) | 2018-01-29 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2019170150A1 (zh) * | 2018-03-09 | 2019-09-12 | 上海科技大学 | 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用 |
| CN111936498B (zh) | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| KR20210141554A (ko) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| WO2020191369A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| CN110204532B (zh) * | 2019-05-15 | 2022-03-08 | 浙江工业大学 | 一种靶向egfr蛋白降解的化合物及其制备方法和应用 |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| WO2021018018A1 (en) * | 2019-07-26 | 2021-02-04 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
| WO2021023233A1 (zh) * | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| WO2021053495A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Bifunctional degraders and their methods of use |
| WO2021058017A1 (en) * | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use |
| CN119019369A (zh) | 2019-10-17 | 2024-11-26 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| JP2023539663A (ja) | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114478532A (zh) * | 2020-10-26 | 2022-05-13 | 上海美志医药科技有限公司 | 靶向降解Btk的化合物及其抗肿瘤用途 |
| US20240246977A1 (en) * | 2020-12-31 | 2024-07-25 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| US20250136620A1 (en) * | 2022-01-17 | 2025-05-01 | Newave Pharmaceutical Inc. | Btk degrader |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2015106292A1 (en) | 2014-01-13 | 2015-07-16 | Coferon, Inc. | Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6847855B2 (ja) * | 2015-04-30 | 2021-03-24 | バイエル ファーマ アクチエンゲゼルシャフト | Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ |
| BR112018008918A8 (pt) * | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| EP3544959A4 (en) * | 2016-11-22 | 2020-11-11 | Dana-Farber Cancer Institute, Inc. | BRUTON TYROSINE KINASE (BTK) DEGRADATION BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE |
-
2017
- 2017-11-22 EP EP17873156.8A patent/EP3544959A4/en not_active Withdrawn
- 2017-11-22 US US16/343,979 patent/US10925967B2/en active Active
- 2017-11-22 AU AU2017363265A patent/AU2017363265B2/en active Active
- 2017-11-22 WO PCT/US2017/063027 patent/WO2018098288A1/en not_active Ceased
- 2017-11-22 JP JP2019527358A patent/JP2019535746A/ja active Pending
- 2017-11-22 KR KR1020197018106A patent/KR20190080956A/ko not_active Withdrawn
- 2017-11-22 CA CA3042294A patent/CA3042294A1/en active Pending
-
2020
- 2020-12-16 US US17/123,955 patent/US11730818B2/en active Active
-
2023
- 2023-06-27 US US18/214,825 patent/US12329821B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535746A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| JP2013522292A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2018522879A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| RU2018119173A (ru) | Производное бензофурана, способ его получения и его применение в медицине | |
| JP2014193925A5 (enExample) | ||
| JP2018516917A5 (enExample) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2018504418A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2018505880A5 (enExample) | ||
| JPWO2019148150A5 (enExample) | ||
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| JP2017533266A5 (enExample) | ||
| JP2011511095A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2020536971A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 |